Related Experiment Video
Updated: May 9, 2026
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Vitamin D receptor BsmІ polymorphism and ovarian cancer risk: a meta-analysis
1Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Objective:
Vitamin D receptor (VDR) FokI polymorphism has been reported to influence ovarian cancer (OC) susceptibility, but the association between VDR BsmI polymorphism and OC risk remains controversial. To clarify the relationship between them, we performed a meta-analysis.
Methods:
A comprehensive literature search was conducted to examine all the eligible studies of VDR BsmI polymorphism and OC risk. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to assess the strength of this association.
Results:
Seven separate comparisons consisting of 1977 OC cases and 2832 healthy controls were included in our meta-analysis. The pooled analyses showed no significant association between VDR BsmI G/A polymorphism and OC in all of the comparisons (AA vs GG: OR, 1.01; P = 0.919; AG vs GG: OR, 1.12; P = 0.087; AG + AA vs GG: OR, 1.10; P = 0.146; AA vs AG + GG: OR, 0.96; P = 0.629). However, subgroup analysis showed a significant contribution of the dominant inheritance model to OC development in the European group: AG + AA vs GG (OR, 1.43; P = 0.029); AG vs GG (OR, 1.46; P = 0.031).
Conclusions:
Vitamin D receptor BsmI G/A gene variant might be a moderate risk factor of OC development in the European population instead of North America or Asian population.
